TABLE 4.
Impact of HPV-16/18 vaccination on recurrence of HPV infections and cervical lesions after LEEP
| HPV types | Outcome | Arm | Overall analysis
|
Analysis restricted to newly detected HPV infections after treatment
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total no. events (# Prevalent/ # Incident) | No. person-years | Rate per 1000 | % vaccine efficacy | 95% CI | Rate per 1000 | % vaccine efficacy (incident) | 95% CI (incident) | |||
| HPV-16/18 | HPV infection | HPV | 12 (8/4) | 678 | 18.2 | 25.2% | [−58, 65] | 7.6 | 57.9% | [−43, 88] |
|
| ||||||||||
| Ctrl | 16 (8/8) | 664 | 24.4 | 18.0 | ||||||
|
| ||||||||||
| Persistent HPV | HPV | 4 (4/0) | 689 | 5.9 | 34.7% | [−131, 82] | 0.0 | 100.0% | N/A | |
|
| ||||||||||
| Ctrl | 6 (4/2) | 665 | 9.1 | 4.5 | ||||||
|
| ||||||||||
| LSIL+ | HPV | 4 (4/0) | 302 | 13.2 | −8.0% | [−339, 73] | 0.0 | 100.0% | N/A | |
|
| ||||||||||
| Ctrl | 4 (2/2) | 326 | 12.3 | 6.1 | ||||||
|
| ||||||||||
| HSIL+ | HPV | 3 (3/0) | 348 | 8.6 | −58.0% | [−857, 74] | 0.0 | 100.0% | N/A | |
|
| ||||||||||
| Ctrl | 2 (1/1) | 367 | 5.4 | 2.7 | ||||||
|
| ||||||||||
| CIN2+ | HPV | 3 (3/0) | 362 | 8.3 | −211.0% | [−2901, 68] | 0.0 | N/A | N/A | |
|
| ||||||||||
| Ctrl | 1 (1/0) | 375 | 2.7 | 0.0 | ||||||
|
| ||||||||||
| HPV-31/33/45 | HPV infection | HPV | 9 (4/5) | 1038 | 9.1 | 56.9% | [8.2, 80] | 5.7 | 72.9% | [29, 90] |
|
| ||||||||||
| Ctrl | 20 (3/17) | 989 | 21.1 | 21.0 | ||||||
|
| ||||||||||
| Persistent HPV | HPV | 2 (2/0) | 1049 | 2.0 | 76.0% | [−11, 95] | 0.0 | 100.0% | N/A | |
|
| ||||||||||
| Ctrl | 8 (1/7) | 1000 | 8.2 | 8.6 | ||||||
|
| ||||||||||
| LSIL+ | HPV | 5 (3/2) | 302 | 16.5 | −8.0% | [−275, 69] | 6.6 | 46.0% | [−194, 90] | |
|
| ||||||||||
| Ctrl | 5 (1/4) | 326 | 15.3 | 12.3 | ||||||
|
| ||||||||||
| HSIL+ | HPV | 3 (3/0) | 348 | 8.6 | 0.0 | N/A | N/A | |||
|
| ||||||||||
| Ctrl | 0 (0/0) | 367 | 0.0 | 0.0 | ||||||
|
| ||||||||||
| CIN2+ | HPV | 0 (0/0) | 362 | 0.0 | 0.0 | N/A | N/A | |||
|
| ||||||||||
| Ctrl | 0 (0/0) | 375 | 0.0 | 0.0 | ||||||
|
| ||||||||||
| Oncogenic HPV | HPV infection | HPV | 71 (25/46) | 4097 | 14.1 | 24.3% | [−7.7, 47] | 11.2 | 36.7% | [1.5, 59] |
|
| ||||||||||
| Ctrl | 85 (20/65) | 3969 | 18.7 | 17.7 | ||||||
|
| ||||||||||
| Persistent HPV | HPV | 22 (14/8) | 4156 | 4.7 | 31.7% | [−19, 61] | 2.2 | 65.5% | [23, 85] | |
|
| ||||||||||
| Ctrl | 30 (9/21) | 4001 | 6.9 | 6.5 | ||||||
|
| ||||||||||
| LSIL+ | HPV | 19 (10/9) | 302 | 62.9 | −57.9% | [−225, 23] | 29.8 | 2.8% | [−141, 61] | |
|
| ||||||||||
| Ctrl | 13 (3/10) | 326 | 39.8 | 30.6 | ||||||
|
| ||||||||||
| HSIL+ | HPV | 7 (6/1) | 348 | 20.1 | −145.8% | [−859, 37] | 2.9 | 47.3% | [−480, 95] | |
|
| ||||||||||
| Ctrl | 3 (1/2) | 367 | 8.2 | 5.4 | ||||||
|
| ||||||||||
| CIN2+ | HPV | 3 (3/0) | 362 | 8.3 | −55.5% | [−834, 74] | 0.0 | 100.0% | N/A | |
|
| ||||||||||
| Ctrl | 2 (1/1) | 375 | 5.3 | 2.7 | ||||||
|
| ||||||||||
| Irrespective of HPV | LSIL+ | HPV | 33 | 302 | 109.2 | −15.0% | [−89, 30] | |||
|
| ||||||||||
| Ctrl | 31 | 326 | 95.0 | |||||||
|
| ||||||||||
| HSIL+ | HPV | 10 | 348 | 28.7 | −163.3% | [−742, 18] | ||||
|
| ||||||||||
| Ctrl | 4 | 367 | 10.9 | |||||||
|
| ||||||||||
| CIN2+ | HPV | 3 | 362 | 8.3 | −55.5% | [−834, 74] | ||||
|
| ||||||||||
| Ctrl | 2 | 375 | 5.3 | |||||||
CI, confidence interval; CIN2, cervical intraepithelial neoplasia type 2; Ctrl, control; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excisional procedure; LSIL, low-grade squamous intraepithelial lesion; N/A, not available.